Skip to main content
Debu Tripathy, et al., The Oncologist
The SystHERs breast cancer study was a fully enrolled, prospective registry study that explored contemporary treatment patterns and outcomes in patients with HER2-positive metastatic breast cancer (MBC), resulting in one of the largest real-world datasets for this population and providing a unique opportunity to assess patients with de novo and recurrent HER2-positive MBC. This article reports baseline characteristics, treatment patterns, patient-reported outcomes, and clinical outcomes in these patient subsets.
Don S. Dizon is the Director of Women's Cancers at Lifespan Cancer Institute, Founder of The Oncology Sexual Health First Responders Clinic at Lifespan Cancer Institute, and Director of Medical Oncology at Rhode Island Hospital. Dr. Dizon is a Professor of Medicine at the Warren Alpert Medical School of Brown University.
A cancer diagnosis is often frightening, even devastating. But the journey from diagnosis through treatment can also be transformative. In this month’s blog, Carolyn Taylor shares with Don Dizon her experience with cancer and how it led to a new-found dedication to global cancer advocacy.
In this month's blog post, Don Dizon and Aditya Bardia discuss the bonds that form not only between physicians and their patients but also with their caregivers during the emotional experience of cancer treatment.
Don Dizon and Charles Blanke discuss how they approach social media, the public, and their patients in this month's blog post.
Immunotherapy enhances a cancer patient’s immune system to fight an array of cancers. Immune checkpoint blockade can, however, induce inflammatory side effects known as immune-related Adverse Events (irAE). Because these rare but serious complications need to be quickly detected and properly treated, The Oncologist is devoting a new series designed to enhance the care of patients who may well benefit from therapeutic strategies that involve one or more these powerful immunotherapies.
Precision Medicine Clinic: Molecular Tumor Board is a case-based series designed to help clinicians optimize molecular testing for their patients. The Editors of The Oncologist encourage institutions to share their findings and experiences to help improve the precision of genomic oncology and fulfill its promise of improved outcomes for patients. This collection highlights a diverse set of patients exhibiting a range of tumor types and mutations.
Opioids form the cornerstone of pain management in cancer patients, but the crisis of opioid addiction has resulted in significant challenges facing patients, physicians, lawmakers, and communities across the nation. This series is focused to help clinicians manage the opioid crisis while ensuring adequate pain management for their patients.
Copyright © The Oncologist Community 2019. All rights reserved.